SG1906
/ Sumgen Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 27, 2025
CSG-1906-101: SG1906 for CLDN18.2-Positive Solid Tumors
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Trial completion date: Aug 2025 ➔ Aug 2027 | Trial primary completion date: Feb 2025 ➔ Feb 2027
Trial completion date • Trial primary completion date • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Solid Tumor • CLDN18
November 21, 2023
CSG-1906-101: SG1906 for CLDN18.2-Positive Solid Tumors
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Phase classification: P1a/1b ➔ P1
Phase classification • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18
May 12, 2023
CSG-1906-101: SG1906 for CLDN18.2-Positive Solid Tumors
(clinicaltrials.gov)
- P1a/1b | N=60 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Metastases • New P1 trial • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18
1 to 3
Of
3
Go to page
1